Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2)

Pharmaceutical Research

Volumn 22, Issue 4, 2005, Pages 613-618

  Kondo, Chihiro ^a   Onuki, Reiko ^a   Kusuhara, Hiroyuki ^a   Suzuki, Hiroshi ^b   Suzuki, Michiko ^a   Okudaira, Noriko ^c   Kojima, Maho ^c   Ishiwata, Kazuya ^c   Jonker, Johan W ^d   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c MEIJI SEIKA KAISHA LTD   (Japan)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Absorption; BCRP ABCG2; Intestinal perfusion; ME3229; Prodrug

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; EF 5084; EF 5139; FIBRINOGEN RECEPTOR ANTAGONIST; ME 3229; ME 3277; PM 10; PM 11; PM 5; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; FILTRATION; INTESTINE ABSORPTION; INTESTINE PERFUSION; MEMBRANE VESICLE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE; STRAIN DIFFERENCE; WILD TYPE;

AMIDES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; CELL LINE; FEMALE; INTESTINAL ABSORPTION; JEJUNUM; MICE; MICE, KNOCKOUT; PERFUSION; PIPERIDINES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRODRUGS; THIOPHENES; TRANSPORT VESICLES;

EID: 20944433769     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11095-005-2487-9     Document Type: Article

References (19)

1. N. Okudaira, T. Tatebayashi, G. C. Speirs, I. Komiya, and Y. Sugiyama. A study of the intestinal absorption of an ester-type prodrug, ME3229, in rats: active efflux transport as a cause of poor bioavailability of the active drug. J. Pharmacol. Exp. Ther. 294:580-587 (2000).
2. N. Okudaira, I. Komiya, and Y. Sugiyama. Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb/IIIa receptor antagonist, in rat small intestine. J. Pharmacol. Exp. Ther. 295:717-723 (2000).
3. J. W. Jonker, J. W. Smit, R. F. Brinkhuis, M. Maliepaard, J. H. Beijnen, J. H. Schellens, and A. H. Schinkel. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92:1651-1656 (2000).
4. J. W. Jonker, M. Buitelaar, E. Wagenaar, M. A. Van Der Valk, G. L. Scheffer, R. J. Scheper, T. Plosch, F. Kuipers, R. P. Elferink, H. Rosing, J. H. Beijnen, and A. H. Schinkel. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. USA 99:15649-15654 (2002).
5. A. E. van Herwaarden, J. W. Jonker, E. Wagenaar, R. F. Brinkhuis, J. H. Schellens, J. H. Beijnen, and A. H. Schinkel. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res. 63:6447-6452 (2003).
6. M. Suzuki, H. Suzuki, Y. Sugimoto, and Y. Sugiyama. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J. Biol. Chem. 278:22644-22649 (2003).
7. L. A. Doyle and D. D. Ross. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358 (2003).
8. M. Muller, C. Meijer, G. J. Zaman, P. Borst, R. J. Scheper, N. H. Mulder, E. G. de Vries, and P. L. Jansen. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA 91:13033-13037 (1994).
9. C. Kondo, H. Suzuki, M. Itoda, S. Ozawa, J. Sawada, D. Kobayashi, I. Ieiri, K. Mine, and K. Ohtsubo. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res. 21:1895-1903 (2004).
10. H. Yuasa, K. Matsuda, and J. Watanabe. Influence of anesthetic regimens on intestinal absorption in rats. Pharm. Res. 10:884-888 (1993).
11. R. M. Loria, H. L. Kayne, S. Kibrick, and S. A. Broitman. Measurement of intestinal absorption in mice by a double-label radioisotope perfusion technic. Lab. Anim. Sci. 26:603-606 (1976).
12. Y. Adachi, H. Suzuki, and Y. Sugiyama. Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharm. Res. 20:1163-1169 (2003).
13. J. Taipalensuu, H. Tornblom, G. Lindberg, C. Einarsson, F. Sjoqvist, H. Melhus, P. Garberg, B. Sjostrom, B. Lundgren, and P. Artursson. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 299:164-170 (2001).
14. N. Mizuno, M. Suzuki, H. Kusuhara, H. Suzuki, K. Takeuchi, T. Niwa, J. W. Jonker, and Y. Sugiyama. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2- methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab. Dispos. 32:898-901 (2004).
15. H. Suzuki and Y. Sugiyama. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci. 12:3-12 (2000).
16. L. Z. Benet, T. Izumi, Y. Zhang, J. A. Silverman, and V. J. Wacher. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J. Control. Rel. 62:25-31 (1999).
17. L. Z. Benet, C. L. Cummins, and C. Y. Wu. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab. 4:393-398 (2003).
18. J. Konig, A. T. Nies, Y. Cui, I. Leier, and D. Keppler. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461:377-394 (1999).
19. T. Satoh and M. Hosokawa. The mammalian carboxylesterases: from molecules to functions. Annu. Rev. Pharmacol. Toxicol. 38:257-288 (1998).